MA32224B1 - Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales - Google Patents

Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales

Info

Publication number
MA32224B1
MA32224B1 MA33241A MA33241A MA32224B1 MA 32224 B1 MA32224 B1 MA 32224B1 MA 33241 A MA33241 A MA 33241A MA 33241 A MA33241 A MA 33241A MA 32224 B1 MA32224 B1 MA 32224B1
Authority
MA
Morocco
Prior art keywords
treatment
carbonyl
pyrazolyl
diseases
retroviral diseases
Prior art date
Application number
MA33241A
Other languages
Arabic (ar)
English (en)
Inventor
Kai Thede
Susanne Greschat
Steffen Wildum
Daniela Paulsen
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of MA32224B1 publication Critical patent/MA32224B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouvelles (pyrazolyl-carbonyl)imidazolidinones (i) substituées, leur procédé de fabrication, leur utilisation pour le traitement et/ou la prophylaxie de maladies, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de maladies rétrovirales, chez l'homme et/ou l'animal.
MA33241A 2008-03-17 2010-10-11 Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales MA32224B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008015033A DE102008015033A1 (de) 2008-03-17 2008-03-17 Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
PCT/EP2009/001714 WO2009115213A1 (fr) 2008-03-17 2009-03-10 Dérivés de (pyrazolyl-carbonyl)imidazolidinone pour le traitement de maladies rétrovirales

Publications (1)

Publication Number Publication Date
MA32224B1 true MA32224B1 (fr) 2011-04-01

Family

ID=40565083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33241A MA32224B1 (fr) 2008-03-17 2010-10-11 Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales

Country Status (22)

Country Link
US (1) US8399682B2 (fr)
EP (1) EP2254885B1 (fr)
JP (1) JP5576853B2 (fr)
KR (1) KR20100124337A (fr)
CN (1) CN101977908B (fr)
AP (1) AP2774A (fr)
AR (1) AR070919A1 (fr)
AU (1) AU2009226656A1 (fr)
CA (1) CA2718685C (fr)
CL (1) CL2009000636A1 (fr)
DE (1) DE102008015033A1 (fr)
IL (1) IL207649A0 (fr)
MA (1) MA32224B1 (fr)
MX (1) MX2010010230A (fr)
NZ (1) NZ588141A (fr)
PE (1) PE20091718A1 (fr)
RU (1) RU2010141578A (fr)
TW (1) TW200951125A (fr)
UA (1) UA102390C2 (fr)
UY (1) UY31717A1 (fr)
WO (1) WO2009115213A1 (fr)
ZA (1) ZA201007361B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
EP2295038B1 (fr) * 2009-09-11 2013-05-29 AiCuris GmbH & Co. KG Dispersion solide comprenant un agent anti-VIH
DE102011055815A1 (de) * 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US3806506A (en) 1971-08-05 1974-04-23 Uniroyal Inc Furan derivatives,compositions thereof and methods for using same
DE3119796A1 (de) 1981-05-19 1982-12-23 Hoechst Ag, 6000 Frankfurt Substituierte tryptaminderivate von thienyloxpropanolaminen, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen sowie ihre verwendung
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5571810A (en) 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH084281B2 (ja) 1992-09-30 1996-01-17 橋本コーポレイション株式会社 オンフック後相手の声を拡声する電話装置
FR2728571B1 (fr) 1994-12-22 1997-01-31 Adir Nouveaux ethers d'oximes tricycliques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5696151A (en) 1995-11-30 1997-12-09 Uniroyal Chemical Company, Inc. Compounds useful for the inhibition of the replication of HIV-1 and HIV-1 mutants
US6143780A (en) 1999-09-17 2000-11-07 Uniroyal Chemical Company, Inc. N-arylmethylthioanilide compounds useful for the inhibition of the replication of HIV
US6919338B2 (en) 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
EP1412347B1 (fr) 2001-08-01 2006-01-11 Basell Polyolefine GmbH Procede de preparation de derives heterocycliques de pentalene
ES2338539T3 (es) 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2004016592A1 (fr) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Inhibiteurs de prenylation et leurs methodes de synthese et d'utilisation
GB0221477D0 (en) * 2002-09-16 2002-10-23 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
JP4419078B2 (ja) 2002-12-02 2010-02-24 アステラス製薬株式会社 ピラゾール誘導体
PL377848A1 (pl) 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pochodne pirazoli
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
WO2004076453A1 (fr) 2003-02-27 2004-09-10 Neurosearch A/S Derives aryle diazabicycliques
FR2856683A1 (fr) 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
ATE517872T1 (de) * 2003-06-26 2011-08-15 Novartis Ag Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
WO2005007625A2 (fr) 2003-07-14 2005-01-27 The University Of Tennessee Research Foundation Amides heterocycliques a activite anti-tuberculinique
US7220772B2 (en) * 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
FR2860792B1 (fr) 2003-10-10 2006-02-24 Sanofi Synthelabo Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
ES2329915T3 (es) 2004-02-20 2009-12-02 Astrazeneca Ab Derivados de 1,5-difenilpirazol 3-sustituidos utiles como moduladores de cb1.
EP1762568A1 (fr) 2004-07-01 2007-03-14 Daiichi Pharmaceutical Co., Ltd. Dérivés de pyrazole
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
MX2007002274A (es) 2004-08-23 2007-05-07 Lilly Co Eli Agentes del receptor de histamina h3. preparacion y usos terapeuticos.
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP1824843A2 (fr) 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibiteurs de proteines kinases
US7741479B2 (en) 2004-12-07 2010-06-22 Locus Pharmaceuticals, Inc. Urea inhibitors of MAP kinases
BRPI0518949A2 (pt) 2004-12-15 2008-12-16 Astrazeneca Ab composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica
EP1858882A1 (fr) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
WO2007009701A2 (fr) 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes pyrazoliniques substitues pour traiter des facteurs de risque cardiovasculaires imputables a des troubles du metabolisme ou de l'alimentation
EP1743637A1 (fr) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés du pyrazole seuls ou en combinaison pour le traitement du syndrome métabolique
GB0516661D0 (en) 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
RU2009117653A (ru) 2006-10-12 2010-11-20 Янссен Фармацевтика Нв (Be) Применение производных замещенного пиразинона в качестве лекарственного средства
EP2099770B1 (fr) 2006-12-21 2015-06-10 Sloan-Kettering Institute for Cancer Research Pyridazinones et composés furanniques
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
DE102008015032A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
CA2718685A1 (fr) 2009-09-24
IL207649A0 (en) 2010-12-30
UY31717A1 (es) 2009-08-31
JP5576853B2 (ja) 2014-08-20
AP2010005422A0 (en) 2010-10-31
KR20100124337A (ko) 2010-11-26
AR070919A1 (es) 2010-05-12
AP2774A (en) 2013-09-30
CL2009000636A1 (es) 2010-05-07
UA102390C2 (ru) 2013-07-10
US8399682B2 (en) 2013-03-19
EP2254885A1 (fr) 2010-12-01
US20110124618A1 (en) 2011-05-26
CA2718685C (fr) 2016-11-29
PE20091718A1 (es) 2009-12-11
EP2254885B1 (fr) 2013-12-04
ZA201007361B (en) 2011-12-28
CN101977908A (zh) 2011-02-16
RU2010141578A (ru) 2012-04-27
AU2009226656A1 (en) 2009-09-24
NZ588141A (en) 2012-05-25
JP2011514366A (ja) 2011-05-06
TW200951125A (en) 2009-12-16
WO2009115213A1 (fr) 2009-09-24
MX2010010230A (es) 2010-11-09
CN101977908B (zh) 2014-04-23
DE102008015033A1 (de) 2009-09-24

Similar Documents

Publication Publication Date Title
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201790267A1 (ru) Новые модуляторы киназ
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA200971077A1 (ru) Гетероциклические модуляторы киназы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201100032A1 (ru) Соединения пиридина
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201170349A1 (ru) Модуляторы mif
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида